Alzheimer’s vaccine research has progressed significantly since the disease was first identified over a hundred years ago, with treatments now available that can reduce harmful proteins in the brain associated with the condition. Vaccine trials are currently underway to eliminate these proteins, with one of the most promising candidates being UB-311 developed by American company Vaxxinity. The synthetic, peptide-based immunotherapy has proved safe and tolerable in phase 2 trials and Japanese healthcare company Eisai recently developed LEQEMBI, a cost-effective vaccine for the disease.
FBI Warns Of Malware Risks In Free Online File Converters: Key Information You Need
The FBI Denver Field Office has warned about a rise in cybercrimes utilising free online file converters. Cybercriminals are using these tools to install malware
